Shuai Liu, Shiyu Fan, Jinghuan Gan, Wang Liao, Qin Chen, Xia Li, Jiewen Zhang, Xiaochun Chen, Yong Ji
{"title":"护理人员对lecanemab用于阿尔茨海默病的看法：中国的一项全国性调查","authors":"Shuai Liu, Shiyu Fan, Jinghuan Gan, Wang Liao, Qin Chen, Xia Li, Jiewen Zhang, Xiaochun Chen, Yong Ji","doi":"10.1002/alz.70680","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Caregivers' decisions significantly influence Alzheimer's disease progression, yet research on the benefits of disease-modifying therapy (DMT) from their perspective is limited.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>This cross-sectional survey included 345 informal caregivers of lecanemab-treated patients. We collected online questionnaires from 37 tertiary hospitals across 31 provinces/autonomous regions/municipalities in China (2024/06/24 ∼ 2024/12/24).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Approximately 94.5% of the caregivers opined that the burden of care did not intensify (including remaining constant or being alleviated) subsequent to the administration of lecanemab, among which 25.8% of the caregivers stated that the burden of care was mitigated. Those caregivers with a higher annual family income (≥¥400,000, <i>p </i>< 0.01) and filial caregivers exhibited greater confidence in the therapeutic efficacy of lecanemab.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Most caregivers hold a positive attitude toward lecanemab, particularly filial caregivers. The application of lecanemab may alleviate the care burden on caregivers.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>We conducted the first China national survey on Alzheimer's disease (AD) caregiver decision-making and lecanemab experience, collecting 345 questionnaires.</li>\n \n <li>The majority of caregivers in China hold a favorable attitude toward lecanemab.</li>\n \n <li>Higher education, younger age, and filial relationships are associated with reduced caregiver burden.</li>\n \n <li>Higher income is linked to increased caregiver confidence and better lecanemab adherence.</li>\n \n <li>There is a low adoption rate of blood-based AD biomarkers in caregiver decisions.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 9","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70680","citationCount":"0","resultStr":"{\"title\":\"Caregivers' perspectives on lecanemab use for Alzheimer's disease: A national survey in China\",\"authors\":\"Shuai Liu, Shiyu Fan, Jinghuan Gan, Wang Liao, Qin Chen, Xia Li, Jiewen Zhang, Xiaochun Chen, Yong Ji\",\"doi\":\"10.1002/alz.70680\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>Caregivers' decisions significantly influence Alzheimer's disease progression, yet research on the benefits of disease-modifying therapy (DMT) from their perspective is limited.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>This cross-sectional survey included 345 informal caregivers of lecanemab-treated patients. We collected online questionnaires from 37 tertiary hospitals across 31 provinces/autonomous regions/municipalities in China (2024/06/24 ∼ 2024/12/24).</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Approximately 94.5% of the caregivers opined that the burden of care did not intensify (including remaining constant or being alleviated) subsequent to the administration of lecanemab, among which 25.8% of the caregivers stated that the burden of care was mitigated. Those caregivers with a higher annual family income (≥¥400,000, <i>p </i>< 0.01) and filial caregivers exhibited greater confidence in the therapeutic efficacy of lecanemab.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Most caregivers hold a positive attitude toward lecanemab, particularly filial caregivers. The application of lecanemab may alleviate the care burden on caregivers.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>We conducted the first China national survey on Alzheimer's disease (AD) caregiver decision-making and lecanemab experience, collecting 345 questionnaires.</li>\\n \\n <li>The majority of caregivers in China hold a favorable attitude toward lecanemab.</li>\\n \\n <li>Higher education, younger age, and filial relationships are associated with reduced caregiver burden.</li>\\n \\n <li>Higher income is linked to increased caregiver confidence and better lecanemab adherence.</li>\\n \\n <li>There is a low adoption rate of blood-based AD biomarkers in caregiver decisions.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 9\",\"pages\":\"\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2025-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70680\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70680\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70680","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Caregivers' perspectives on lecanemab use for Alzheimer's disease: A national survey in China
INTRODUCTION
Caregivers' decisions significantly influence Alzheimer's disease progression, yet research on the benefits of disease-modifying therapy (DMT) from their perspective is limited.
METHODS
This cross-sectional survey included 345 informal caregivers of lecanemab-treated patients. We collected online questionnaires from 37 tertiary hospitals across 31 provinces/autonomous regions/municipalities in China (2024/06/24 ∼ 2024/12/24).
RESULTS
Approximately 94.5% of the caregivers opined that the burden of care did not intensify (including remaining constant or being alleviated) subsequent to the administration of lecanemab, among which 25.8% of the caregivers stated that the burden of care was mitigated. Those caregivers with a higher annual family income (≥¥400,000, p < 0.01) and filial caregivers exhibited greater confidence in the therapeutic efficacy of lecanemab.
DISCUSSION
Most caregivers hold a positive attitude toward lecanemab, particularly filial caregivers. The application of lecanemab may alleviate the care burden on caregivers.
Highlights
We conducted the first China national survey on Alzheimer's disease (AD) caregiver decision-making and lecanemab experience, collecting 345 questionnaires.
The majority of caregivers in China hold a favorable attitude toward lecanemab.
Higher education, younger age, and filial relationships are associated with reduced caregiver burden.
Higher income is linked to increased caregiver confidence and better lecanemab adherence.
There is a low adoption rate of blood-based AD biomarkers in caregiver decisions.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
